GSK and 23andMe entered a 4-year exclusive collaboration to develop novel medicines and vaccines using 23andMe's human genetics database. GSK invested $300M in 23andMe equity for access to its consumer genetic data to identify drug targets. The partnership aimed to use genetic insights to improve drug development success rates across multiple therapeutic areas.
Key facts
AnnouncedJul 25, 2018
Deal value$300M
Deal typeCo-Development
Key assets23andMe genetic database (consumer genotype-phenotype research platform), Drug target identification platform, GSK LRRK2 inhibitor (undisclosed code at deal announcement)